Lacosamide Krka (Lacosamide)

Lacosamide works by enhancing the slow inactivation of voltage‑gated sodium channels in neurons. This action stabilizes hyper‑excitable neuronal membranes, reduces repetitive firing, and limits the spread of epileptiform activity, thereby decreasing the likelihood of seizure occurrence.

The dosage of lacosamide is individualized by the prescribing clinician based on the patient’s age, renal and hepatic function, and seizure control needs. The prescriber determines the starting dose and any titration schedule, following approved labeling and clinical guidelines.

Safety data for lacosamide during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss potential exposure with their healthcare provider, as the drug may be present in breast milk.

To order Lacosamide Krka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional AEDs that target fast inactivation. Compared with drugs like carbamazepine or phenytoin, lacosamide often has a lower risk of drug‑induced hyponatremia and may be better tolerated, though individual response varies and selection should be based on clinical judgment.

Lacosamide Krka tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. No special refrigeration is required.

Lacosamide Krka is taken orally as a tablet. Swallow the tablet whole with a glass of water; it may be taken with or without food. Follow the prescriber’s instructions regarding timing and whether the dose should be taken once or twice daily.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, cardiac conduction abnormalities (e.g., PR‑interval prolongation), and emergence of suicidal thoughts or behavior. Patients should seek immediate medical attention if they notice rash, chest discomfort, irregular heartbeat, or mood changes.

Lacosamide should be avoided in individuals with known hypersensitivity to the drug or its excipients, and in patients with severe cardiac conduction disorders such as advanced atrioventricular block unless a pacemaker is in place. Caution is also advised for those with significant renal or hepatic impairment.